Breaking News Instant updates and real-time market news.

NVO

Novo Nordisk

$47.35

0.13 (0.28%)

, HURN

Huron

$49.51

1.08 (2.23%)

04:55
01/06/19
01/06
04:55
01/06/19
04:55

Leading Biotech to hold a conference

Boston Biotech East/West CEO Conference will be held in San Francisco on January 5-6.

NVO

Novo Nordisk

$47.35

0.13 (0.28%)

HURN

Huron

$49.51

1.08 (2.23%)

PFE

Pfizer

$42.99

0.95 (2.26%)

ZLAB

Zai Lab

$22.02

0.33 (1.52%)

SRNE

Sorrento Therapeutics

$2.57

0.09 (3.63%)

JNJ

Johnson & Johnson

$127.80

1.99 (1.58%)

BAYRY

Bayer

$0.00

(0.00%)

DNLI

Denali Therapeutics

$20.30

1.72 (9.26%)

ARCT

Arcturus Therapeutics

$5.10

0.25 (5.15%)

ANAB

AnaptysBio

$65.27

3.74 (6.08%)

NVS

Novartis

$85.88

1.1 (1.30%)

MRTX

Mirati Therapeutics

$44.94

1.03 (2.35%)

AGN

Allergan

$142.64

6.59 (4.84%)

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 07

    Jan

  • 07

    Jan

  • 07

    Jan

  • 14

    Jan

  • 17

    Jan

  • 22

    Jan

  • 27

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 18

    Feb

  • 12

    Mar

  • 18

    May

  • 28

    May

NVO Novo Nordisk
$47.35

0.13 (0.28%)

12/11/18
JEFF
12/11/18
INITIATION
JEFF
Hold
Novo Nordisk assumed with a Hold at Jefferies
Jefferies analyst Peter Welford assumed coverage of Novo Nordisk with a Buy rating and DKK 285 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum." He calls Novo his least preferred stock in the group.
11/26/18
PART
11/26/18
UPGRADE
PART
Buy
Novo Nordisk upgraded to Buy from Hold at Pareto
11/19/18
JPMS
11/19/18
UPGRADE
JPMS
Overweight
Novo Nordisk upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser upgraded Novo Nordisk to Overweight and raised his price target for the shares to 340 kroner from 290 kroner. The analyst sees the company's growth strengthening through 2019.
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
HURN Huron
$49.51

1.08 (2.23%)

09/19/18
WBLR
09/19/18
NO CHANGE
WBLR
Outperform
Huron has 'hidden asset' with Shorelight Education, says William Blair
William Blair analyst Timothy McHugh believes Huron Consulting Group's investment in privately held Shorelight Education is an "overlooked" and "hidden" asset. Shorelight helps universities recruit and educate non-U.S. students, the analyst tells investors in a research note. He points out that the number of students enrolled worldwide in foreign countries increased annually at a 6% from 2000 to 2014, and is expected to grow at a 4%-5% rate through 2025. Huron carried the 20% ownership interest in Shorelight on its balance sheet at $47M last quarter, which is up from $35M most of last year, McHugh writes. The analyst believes the value of Huron's investment could be "meaningfully higher" if assuming $100M to $150M of revenue and a 3-7 times revenue multiple. McHugh keeps an Outperform rating on Huron Consulting Group.
08/28/18
BRRR
08/28/18
UPGRADE
Target $55
BRRR
Outperform
Huron upgraded to Outperform from Market Perform at Barrington
Barrington analyst Kevin Steinke upgraded Huron Consulting Group to Outperform with a price target of $55. The analyst believes the company's Healthcare segment is poised for a rebound with margins set to improve beyond 2018. Commentary about the Healthcare segment on Huron's Q2 conference call "changed meaningfully," as management expressed optimism in the sustainability of improved demand compared to its cautiousness in recent quarters, Steinke tells investors in a research note.
08/01/18
08/01/18
UPGRADE
Target $52

Buy
Huron upgraded to Buy with $52 price target at Benchmark
As previously reported, Benchmark analyst Bill Sutherland upgraded Huron to Buy from Hold after all three of its segments produced better revenue trends in Q2. He believes this demonstrates the pay off from recent initiatives to reposition and views the company as well positioned given its focus on Healthcare and Higher Education, which Sutherland calls two sectors with expanding operating and financial challenges. He set a $52 price target on Huron shares.
08/01/18
BNCH
08/01/18
UPGRADE
BNCH
Buy
Huron upgraded to Buy from Hold at Benchmark
PFE Pfizer
$42.99

0.95 (2.26%)

12/28/18
BTIG
12/28/18
NO CHANGE
Target $190
BTIG
Buy
Sarepta's recent weakness represents 'buying opportunity', says BTIG
BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta (SRPT), noting that while the stock was among the best performing biotech names this year, its recent weakness represents a "potential buying opportunity". The analyst believes that the company's AAVrh74 micro-dystrophin gene therapy for the treatment of Duchenne Muscular Dystrophy program leads those of Pfizer (PFE) and Solid Biosciences (SLDB) and expects Sarepta to reach about $2B in peak U.S. sales by 2024.
01/03/19
01/03/19
INITIATION

Pfizer initiates Phase 2b/3 clinical trial for PF-06651600
Pfizer announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies. Based on the totality of the data and the emerging clinical profile, PF-06651600 was granted Breakthrough Therapy designation from FDA for the treatment of alopecia areata in September 2018. PF-06651600 will also continue to be evaluated for rheumatoid arthritis, Crohn's disease and ulcerative colitis.
12/31/18
CANT
12/31/18
NO CHANGE
Target $53
CANT
Overweight
Doctors impressed by tanezumab data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that investors she's spoken with are expecting the data for Pfizer (PFE) and Eli Lilly's (LLY) tanezumab in the first half of 2019 to be similar to or worse than what was seen in the first Phase 3 data set reported on October 23. However, physicians are impressed by the data and do not believe the rapidly progressive osteoarthritis imbalance would impact their desire to prescribe tanezumab if it is approved, Chen tells investors in a research note. The analyst believes the safety for tanezumab will be better than expected and that the drug could replace opioids for the treatment of pain. If that is right, peak sales potential of tanezumab could be billions of dollars, and drive upside to modest expectations for the drug, says the analyst. She keeps an Overweight rating on Pfizer with a $53 price target.
12/27/18
ARGS
12/27/18
NO CHANGE
Target $47
ARGS
Buy
GlaxoSmithKline's high dividend yield 'attractive', says Argus
Argus analyst John Eade kept his Buy rating and $47 price target on GlaxoSmithKline (GSK) with a positive view on its planned joint venture with Pfizer (PFE) combining the companies' consumer businesses. The analyst expects the transaction to boost GlaxoSmithKline shares in the next 2-3 years. Eade also cites the company's 5.2% dividend yield, which he sees as "attractive in a low-interest-rate environment."
ZLAB Zai Lab
$22.02

0.33 (1.52%)

02/14/18
JPMS
02/14/18
UPGRADE
Target $35
JPMS
Overweight
Zai Lab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Zai Lab to Overweight and raised his price target for the shares to $35 from $32. The analyst continues to view the company as an attractive healthcare emerging markets story in China, and now believes shares represent an attractive long-term entry point. The analyst adds that the FPA144 deal is an "underappreciated oncology tuck-in, with a meaningful target market opportunity."
11/21/18
JEFF
11/21/18
INITIATION
Target $34
JEFF
Buy
Zai Lab initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Zai Lab with a Buy rating and $34 price target. The analyst likes the company's structure of forming partnerships around assets that are already clinically de-risked. The partnerships reduce risk and allow Zai Lab to accelerate a drug's path to market in China, Raycroft tells investors in a research note.
06/21/18
LEER
06/21/18
INITIATION
Target $43
LEER
Outperform
Zai Lab assumed with an Outperform at Leerink
Leerink analyst Jonathan Chang assumed coverage of Zai Lab with an Outperform rating and $43 price target as he believes it is well-positioned to execute.
SRNE Sorrento Therapeutics
$2.57

0.09 (3.63%)

12/12/18
HCWC
12/12/18
NO CHANGE
HCWC
Buy
Sorrento Therapeutics has multiple catalysts in 2019, says H.C. Wainwright
2019 should represent a turning point for Sorrento Therapeutics, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The analyst believes the company is in position to report "multiple value-driving clinical data catalysts" over the course of 2019, both with its pain management portfolio and its cancer immunotherapy candidates. He thinks the interest in anti-CD38 CAR-T approaches has only increased following the recently concluded American Society for Hematology annual meeting. Further, Sorrento's recent financing transactions "provide a pathway to sustainability," adds Selvaraju. He reiterates a Buy rating on the shares with a $40 price target.
06/28/18
RILY
06/28/18
INITIATION
Target $14.25
RILY
Buy
Sorrento Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Sorrento Therapeutics with a Buy rating and $14.25 price target.
02/28/18
HCWC
02/28/18
NO CHANGE
Target $38
HCWC
Buy
Sorrento price target raised to $38 after ZTlido approval at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju noted that Sorrento Therapeutics' receipt of FDA approval of ZTlido, the company's next-generation topical lidocaine product, came on schedule on the previously-announced PDUFA date of February 28. The analyst, who notes the product is entering the pain management market at a time when promotion of other topical lidocaine products "has virtually disappeared," believes ZTlido could prove to be popular and have a relatively swift commercial ramp. He raised his price target on Sorrento shares to $38 from $35 following the approval and keeps a Buy rating on the stock.
04/03/18
HCWC
04/03/18
NO CHANGE
Target $40
HCWC
Buy
Sorrento target raised to $40 after completed financing at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Sorrento Therapeutics to $40 from $38 saying the recently completed convertible note financing "provides ample runway." The company now has a sufficient cash runway to fund operations for at least the next 24 months, which removes a near-term overhang, Selvaraju tells investors in a research note. He reiterates a Buy rating on Sorrento.
JNJ Johnson & Johnson
$127.80

1.99 (1.58%)

01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Outperform
No change in talc litigation risk for Johnson & Johnson, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that the NY Times reported that Johnson & Johnson has lost its bid to overturn the $4.7B in a talc trial in St. Louis in July 2018. After checking with the company, the analyst is "able to confirm" that the decision relates to the trial judge denying Johnson & Johnson's post trial motion to set aside the $4.7B verdict. Biegelsen understands that the company had to file this motion in order to file its actual appeal of the decision with the appellate court. As such, he believes the judge's decision should not materially affect the overall talc situation for Johnson & Johnson. Wells Fargo has an Outperform rating on the shares.
BAYRY Bayer
$0.00

(0.00%)

12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Neutral
Bayer downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Vosser downgraded Bayer to Neutral and lowered his price target for the shares to EUR 70 from EUR 100. The analyst believes 2019 will be another "messy year" for the company.
12/17/18
MSCO
12/17/18
NO CHANGE
Target $153
MSCO
Equal Weight
J&J stock reaction, comparisons to Bayer 'flawed,' says Morgan Stanley
Morgan Stanley analyst David Lewis said he is not convinced that Friday's article from Reuters uncovered new evidence that was not presented to Johnson & Johnson (JNJ) juries or part of the ongoing legal discovery process, but that it has raised a level of awareness around the issue and may inflate the company's potential legal exposure. The stock reaction is not supported by science as linking ovarian cancer broadly to talc will be challenging, contends Lewis, who believes the selloff in J&J shares appears too severe. Additionally, investor concerns that talc issues could lead to a Bayer-like (BAYRY) reaction have a flaw in the analysis of financial exposure, as glyphosate and its derivatives represent about 30% of Bayer's corporate EBITDA, while baby powder is less than 0.3% of J&J's sales and an "immaterial" percentage of EBITDA, said Lewis. He maintains an Equal Weight rating on Johnson & Johnson with a price target of $153.
12/04/18
FBCO
12/04/18
NO CHANGE
Target $113
FBCO
Outperform
FMC Corporation price target raised to $113 from $105 at Credit Suisse
Credit Suisse analyst Christopher Parkinson raised his price target for FMC Corporation (FMC) to $113 from $105 as he believes the company is making impressive strides to solidify itself within the "Big 5" alongside Bayer (BAYRY), Syngenta, BASF (BASFY) and DowDuPont (DWDP) post a large round of consolidation. The analyst reiterates an Outperform rating on the shares.
DNLI Denali Therapeutics
$20.30

1.72 (9.26%)

12/11/18
CANT
12/11/18
NO CHANGE
Target $25
CANT
Overweight
Denali Therapeutics pipeline increasingly visible, says Cantor Fitzgerald
After attending the company's R&D day, Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Denali Therapeutics with a $25 price target. The company is approaching neurodegenerative diseases through "rigorous" therapeutic discovery and development, and its "increasingly visible" pipeline progress will enhance investor conviction over the next 12-18 months, Duncan tells investors in a research note.
11/14/18
CANT
11/14/18
INITIATION
Target $25
CANT
Overweight
Denali Therapeutics initiated with an Overweight at Cantor Fitzgerald
Price target $25.
11/15/18
CANT
11/15/18
INITIATION
Target $25
CANT
Overweight
Denali Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Denali Therapeutics with an Overweight rating and $25 price target. The analyst rolled out coverage on five Neuro-Innovator companies, focusing on "innovative technologies that can lead to breakthrough and disruptive treatments." He believes all five companies have "growth potential that exceeds current valuations, over time."
11/12/18
11/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Denali Therapeutics (DNLI) initiated with a Buy at Janney Montgomery Scott. 2. PhaseBio (PHAS) initiated with a Buy at Stifel and Citi as well as an Outperform at Cowen. 3. Osmotica Pharmaceuticals (OSMT) initiated with a Buy at Jefferies as well as an Outperform at Wells Fargo and RBC Capital. 4. SI-Bone (SIBN) initiated with an Outperform at JMP Securities, an Overweight at Morgan Stanley, as well as a Buy at Canaccord and BofA/Merrill. 5. Studio City (MSC) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ARCT Arcturus Therapeutics
$5.10

0.25 (5.15%)

09/20/18
09/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ralph Lauren (RL) upgraded to Neutral from Underweight at Piper Jaffray with analyst Erinn Murphy, who remains concerned about the sustainability of Ralph Lauren's sales group, saying earnings estimates are likely to continue to grind higher given the company's "sound" cost control and favorable margin mix shift. 2. Caterpillar (CAT) upgraded to Outperform from Neutral at Baird with analyst Mig Dobre saying he believes demand growth should continue into 2019. 3. Copart (CPRT) upgraded to Buy from Hold at Gabelli with analyst Matthew Paige saying he raised his valuation multiple to 15x EBITDA from 12x to reflect the premium he believes the stock deserves relative to KAR Auction Service (KAR) given its EBITDA margin advantage and his view that current market conditions better support the salvage auction business than wholesale. 4. Arcturus Therapeutics (ARCT) upgraded to Strong Buy from Buy at WBB Securities. 5. First BanCorp (FBP) upgraded to Buy from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/11/18
WBBS
06/11/18
UPGRADE
WBBS
Buy
Arcturus Therapeutics upgraded to Buy from Hold at WBB Securities
09/20/18
WBBS
09/20/18
UPGRADE
WBBS
Strong Buy
Arcturus Therapeutics upgraded to Strong Buy from Buy at WBB Securities
05/31/18
LTCO
05/31/18
UPGRADE
Target $22
LTCO
Buy
Ladenburg sees 'great upside potential' in Arcturus, upgrades to Buy
Ladenburg Thalmann analyst Wangzhi Li upgraded Arcturus Therapeutics to Buy from Neutral with a $22 price target. By reaching a settlement with the appointment of four new independent directors and termination of all pending litigation, the company removed an organizational overhang since early February, Li tells investors in an intraday research note. The analyst is "encouraged" by the settlement agreement and management reinstatement. Li believes Arcturus can now focus on its normal operation to advance its Lunar and Una platforms, RNA therapeutics pipelines and multiple partnerships. The stock has "great upside potential," Li writes.
ANAB AnaptysBio
$65.27

3.74 (6.08%)

12/20/18
HCWC
12/20/18
INITIATION
Target $126
HCWC
Buy
AnaptysBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started AnaptysBio with a Buy rating and $126 price target. While the company "emerges as a newcomer in the competitive field of inflammatory diseases," it may differentiate itself with a "double play of two wholly owned assets (novel targets) and a proprietary antibody platform," Fein tells investors in a research note. AnaptysBio is "studded with" two clinical stage biologics, five ongoing clinical programs, two licensing partners, and an array of data readouts in the next 12-18 months, says the analyst.
11/21/18
JPMS
11/21/18
INITIATION
Target $115
JPMS
Overweight
AnaptysBio initiated with an Overweight at JPMorgan
JPMorgan started AnaptysBio with an Overweight rating and $115 price target.
11/21/18
11/21/18
INITIATION
Target $115

Overweight
JPMorgan sees attractive entry point, starts AnaptysBio at Overweight
As previously reported, JPMorgan analyst Anupam Rama started AnaptysBio with an Overweight rating and $115 price target, stating that he sees an attractive entry point with the stock down over 35% since early October. The company's proprietary antibody development approach has been validated by both data and partnerships, while its lead asset etokimab has delivered positive early-stage data in both atopic dermatitis and eosinophilic asthma, Rama tells investors.
10/24/18
CANT
10/24/18
NO CHANGE
Target $68
CANT
Overweight
Cantor Fitzgerald sees nothing fundamental for Tesaro weakness
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating and $68 price target on Tesaro's (TSRO) shares as she sees nothing fundamental on recent weakness. While she acknowledges that the stock is down around 28% since ESMO, the analyst pointed out that the AstraZeneca's (AZN) SOLO1 data is a positive read for the niraparib PRIMA study that will read out in 2H 2019. Further, Young believes that key catalysts for Tesaro remain SITC - GARNET and AMBER data, pivotal data in endometrial for its PD-1 licensed from AnaptysBio (ANAB), and PRIMA data in first line ovarian in 2H 2019.
NVS Novartis
$85.88

1.1 (1.30%)

12/11/18
JEFF
12/11/18
INITIATION
Target $105
JEFF
Buy
Novartis assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum."
12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Underweight
Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company's pipeline and believes the shares are close to fair value.
MRTX Mirati Therapeutics
$44.94

1.03 (2.35%)

09/27/18
COWN
09/27/18
NO CHANGE
COWN
Outperform
Mirati Therapeutics weakness a buying opportunity, says Cowen
Cowen analyst Chris Sibutani said he sees the pullback in Mirati Therapeutics shares as an attractive buying opportunity and reiterates his Outperform rating on the stock. There was never a reason to expect that Mirati's data was under consideration for a late-breaking abstract presentation at ESMO, Sibutani tells investors. He expects management to share their plans for the sitravatinib + nivolumab pivotal study program at the ESMO meeting after data is presented on Monday, October 22. The analyst maintains an Outperform rating on Mirati shares.
11/30/18
RILY
11/30/18
INITIATION
Target $60
RILY
Buy
Mirati Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty started Mirati Therapeutics with a Buy rating and $60 price target.
11/07/18
OPCO
11/07/18
NO CHANGE
Target $57
OPCO
Outperform
Mirati Therapeutics price target lowered to $57 from $62 at Oppenheimer
Oppenheimer analyst Leah Rush Cann lowered his price target for Mirati Therapeutics to $57 from $62 to account for higher shares outstanding. The analyst reiterates an Outperform rating on the stock.
10/29/18
GUGG
10/29/18
UPGRADE
GUGG
Buy
Mirati Therapeutics upgraded to Buy from Neutral at Guggenheim
AGN Allergan
$142.64

6.59 (4.84%)

01/02/19
01/02/19
DOWNGRADE
Target $39

Underweight
Morgan Stanley sees more underperformance for Hologic, downgrades to Underweight
As previously reported, Morgan Stanley analyst David Lewis downgraded Hologic (HOLX) to Underweight from Equal Weight, stating that his checks with about 40 medspas highlighted market saturation of body sculpting devices. This, coupled with Allergan's (AGN) recent announcement of discounting CoolSculpting to drive its installed base, suggests Hologic's acquisition of Cynosure may not be as accretive as expected, Lewis tells investors. Additionally, in the company's Surgical segment, he expects NovaSure will continue to lose share as procedures shift to the office where NovaSure is less popular given periprocedural pain. Given both of these views, Lewis views Hologic as less attractive relative to peers and cut his price target on the stock to $39 from $44.
12/19/18
RAJA
12/19/18
NO CHANGE
Target $198
RAJA
Outperform
Selloff in Allergan shares 'overdone,' says Raymond James
Raymond James analyst Elliot Wilbur notes that the French regulatory authority ANSM has issued a communique indicating that Allergan's CE Mark for the company's line of textured breast implants sold in various European countries will not be renewed based on input from GMED, the official French medical device certification body. Allergan can no longer sell textured breast implants in France and other affected European markets, and the company has ceased sales and commenced a recall of all existing supply, he adds. The analyst acknowledges that this is a "surprise but certainly not an unknown." Further, Wilbur believes reaction is "overdone" and shares should be "aggressively accumulated" on the move. He reiterates an Outperform rating and $198 price target on the stock.
12/19/18
LEER
12/19/18
NO CHANGE
LEER
Outperform
Allergan selloff today a buying opportunity, says Leerink
Leerink analyst Marc Goodman views today's 7% selloff in shares of Allergan based on the breast implant news as a buying opportunity. While the suspension of sales is an incremental negative and likely to bring down consensus numbers, 2019 should bring increasingly visibility for Botox durability and the company's the pipeline, Goodman tells investors in a research note. He keeps an Outperform rating on Allergan, which is down $11.01 to $135.82 in afternoon trading.

TODAY'S FREE FLY STORIES

COP

ConocoPhillips

$65.69

-2.21 (-3.25%)

, SNP

Sinopec

$77.78

-1.96 (-2.46%)

21:01
01/22/19
01/22
21:01
01/22/19
21:01
Periodicals
Breaking Periodicals news story on ConocoPhillips, Sinopec »

Sinopec and…

COP

ConocoPhillips

$65.69

-2.21 (-3.25%)

SNP

Sinopec

$77.78

-1.96 (-2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 28

    May

ALPN

Alpine Immune Sciences

$5.79

(0.00%)

20:50
01/22/19
01/22
20:50
01/22/19
20:50
Hot Stocks
Alpine Immune Sciences CEO buys 191K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LW

Lamb Weston

$70.75

-0.145 (-0.20%)

20:36
01/22/19
01/22
20:36
01/22/19
20:36
Upgrade
Lamb Weston rating change at Stifel »

Lamb Weston upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$115.15

-1.675 (-1.43%)

, UTX

United Technologies

$111.23

-2.7 (-2.37%)

20:25
01/22/19
01/22
20:25
01/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMB

Kimberly-Clark

$115.15

-1.675 (-1.43%)

UTX

United Technologies

$111.23

-2.7 (-2.37%)

ABT

Abbott

$71.56

0.13 (0.18%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

PG

Procter & Gamble

$90.50

-0.89 (-0.97%)

PGR

Progressive

$63.18

-1.24 (-1.92%)

APH

Amphenol

$81.06

-1.41 (-1.71%)

SYF

Synchrony

$26.55

0.27 (1.03%)

WAT

Waters

$203.52

-3.315 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 27

    Jan

  • 30

    Jan

  • 11

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

TXRH

Texas Roadhouse

$66.00

-1 (-1.49%)

20:23
01/22/19
01/22
20:23
01/22/19
20:23
Downgrade
Texas Roadhouse rating change at Stifel »

Texas Roadhouse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$83.34

-2.27 (-2.65%)

, JBLU

JetBlue

$17.36

-0.24 (-1.36%)

19:49
01/22/19
01/22
19:49
01/22/19
19:49
Hot Stocks
Normal operations at Newark Airport have resumed after reported drone activity »

Newark International…

UAL

United Continental

$83.34

-2.27 (-2.65%)

JBLU

JetBlue

$17.36

-0.24 (-1.36%)

AAL

American Airlines

$32.75

-1.21 (-3.56%)

LUV

Southwest

$50.54

-1.04 (-2.02%)

DAL

Delta Air Lines

$47.10

-1 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 04

    Mar

PLL

Piedmont Lithium

$7.60

(0.00%)

19:35
01/22/19
01/22
19:35
01/22/19
19:35
Hot Stocks
Piedmont Lithium initiates 25K meter drill program »

Piedmont Lithium Limited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSBC

Great Southern Bancorp

$49.85

-0.7 (-1.38%)

19:34
01/22/19
01/22
19:34
01/22/19
19:34
Earnings
Great Southern Bancorp reports preliminary Q4 EPS $1.21, consensus $1.12 »

Reports Q4 NII $44.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 13

    Feb

  • 14

    Feb

BAYRY

Bayer

$0.00

(0.00%)

19:08
01/22/19
01/22
19:08
01/22/19
19:08
Periodicals
Bayer requests that CA judge limit evidence in Roundup trial, Reuters says »

Bayer's Monsanto has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$413.28

-6.01 (-1.43%)

19:07
01/22/19
01/22
19:07
01/22/19
19:07
Hot Stocks
BlackRock CEO sells 30.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

  • 11

    Feb

EHTH

eHealth

$45.38

-0.85 (-1.84%)

, ARAY

Accuray

$3.97

0.09 (2.32%)

19:01
01/22/19
01/22
19:01
01/22/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

EHTH

eHealth

$45.38

-0.85 (-1.84%)

ARAY

Accuray

$3.97

0.09 (2.32%)

NAVI

Navient

$10.87

-0.05 (-0.46%)

IBM

IBM

$122.34

-1.49 (-1.20%)

CNMD

Conmed

$66.62

-0.03 (-0.05%)

PUMP

ProPetro Holding

$14.96

-0.49 (-3.17%)

AMTD

TD Ameritrade

$54.96

-0.38 (-0.69%)

TBNK

Territorial Bancorp

$26.90

-0.26 (-0.96%)

APHA

Aphria

$7.07

0.41 (6.16%)

TSE

Trinseo

$48.54

-2.78 (-5.42%)

COF

Capital One

$83.38

-1.62 (-1.91%)

QUOT

Quotient Technology

$10.99

-0.55 (-4.77%)

IBKR

Interactive Brokers

$51.92

-2.82 (-5.15%)

PTCT

PTC Therapeutics

$33.08

-1.245 (-3.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 10

    Feb

  • 11

    Feb

  • 13

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 18

    May

  • 23

    Jan

  • 25

    Jan

APHA

Aphria

$7.07

0.41 (6.16%)

18:55
01/22/19
01/22
18:55
01/22/19
18:55
Hot Stocks
Green Growth files offer to acquire Aphria »

Green Growth Brands Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$33.69

0.24 (0.72%)

18:42
01/22/19
01/22
18:42
01/22/19
18:42
Hot Stocks
Logitech CEO says 'we had a very strong quarter' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

WBA

Walgreens Boots Alliance

$71.59

-0.81 (-1.12%)

18:39
01/22/19
01/22
18:39
01/22/19
18:39
Periodicals
Walgreens to pay $269.2M to resolve U.S. fraud suits, Reuters reports »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

SMBC

Southern Missouri Bancorp

$32.22

-0.29 (-0.89%)

18:35
01/22/19
01/22
18:35
01/22/19
18:35
Earnings
Southern Missouri Bancorp sees Q2 adjusted EPS 81c, consensus 72c »

Southern Missouri…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$31.41

-2.52 (-7.43%)

18:32
01/22/19
01/22
18:32
01/22/19
18:32
Hot Stocks
Zillow's StreetEasy unveils new Listing Tools platform »

StreetEasyunveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$32.44

-0.71 (-2.14%)

, VIAB

Viacom

$29.22

-0.87 (-2.89%)

18:25
01/22/19
01/22
18:25
01/22/19
18:25
Hot Stocks
Viacom to acquire Pluto TV for $340M in cash »

Viacom Inc. announced…

VIA

Viacom

$32.44

-0.71 (-2.14%)

VIAB

Viacom

$29.22

-0.87 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

GOOG

Alphabet

$1,070.72

-27.53 (-2.51%)

, GOOGL

Alphabet Class A

$1,078.68

-28.24 (-2.55%)

18:23
01/22/19
01/22
18:23
01/22/19
18:23
Periodicals
Google spent company-record $21.2M on U.S. lobbying in 2018, Reuters says »

Alphabet's Google…

GOOG

Alphabet

$1,070.72

-27.53 (-2.51%)

GOOGL

Alphabet Class A

$1,078.68

-28.24 (-2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

VIA

Viacom

$32.44

-0.71 (-2.14%)

, VIAB

Viacom

$29.22

-0.87 (-2.89%)

18:16
01/22/19
01/22
18:16
01/22/19
18:16
Periodicals
Viacom to buy Pluto TV for $340M in cash, THR reports »

Viacom will pay $340M in…

VIA

Viacom

$32.44

-0.71 (-2.14%)

VIAB

Viacom

$29.22

-0.87 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

AZZ

AZZ Inc.

$45.09

-0.67 (-1.46%)

18:13
01/22/19
01/22
18:13
01/22/19
18:13
Earnings
AZZ Inc. sees FY20 EPS $2.25-$2.75, consensus $2.54 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.80

-3.46 (-1.14%)

18:13
01/22/19
01/22
18:13
01/22/19
18:13
Hot Stocks
Elon Musk says Tesla Sentry Mode 'coming soon' for cars with Enhanced Autopilot »

Tesla CEO Elon Musk said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

NCOM

National Commerce

$39.07

-0.03 (-0.08%)

18:01
01/22/19
01/22
18:01
01/22/19
18:01
Earnings
National Commerce reports Q4 EPS 51c, consensus 68c »

Reports Q4 NII $43.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$122.34

-1.49 (-1.20%)

18:01
01/22/19
01/22
18:01
01/22/19
18:01
Hot Stocks
IBM says Red Hat acquisition will help accelerate leadership in hybrid cloud »

Says tax was a headwind…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

UAL

United Continental

$83.34

-2.27 (-2.65%)

17:57
01/22/19
01/22
17:57
01/22/19
17:57
Periodicals
United Continental says FAA initiated ground stop for all Newark traffic 

Reported by Bloomberg.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

AQMS

Aqua Metals

$2.16

0.07 (3.35%)

17:55
01/22/19
01/22
17:55
01/22/19
17:55
Hot Stocks
Aqua Metals director Shariq Yosufzai buys 10,000 shares of company stock »

Aqua Metals director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.